Dr. Ogdie on emerging PsA tx: “It’s not just about the pharmacotherapy but also about making the patient feel better” Also, weight loss is incredibly important but also incredibly hard. Losing weight is more impt than the type of diet a patient should be on. #ACR25 @RheumNow https://t.co/FN3EEowkDP

Why do we need to identify early PsA? 🔅Improve symptoms 🔅Prevent radiographic progression 🔅Preserve function ☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos. #ACR25 @RheumNow https://t.co/sEGXzd8RiD

What are the RFs for progression of Pso to PsA? 🔸PsO disease severity - 3.2x risk —>PsA 🔸Phenotype - nail involvement 🔸Obesity - 6x higher risk of developing PsA 🔸MSK symptoms - arthralgia & heel pain #ACR25 @RheumNow https://t.co/UPXuxBPyKI

The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWACHy

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/grsgHFQic5

Is tocilizumab equally effective in ischemic vs. non-ischemic GCA? Ischemic = vision, jaw claudication, or CVA Remission at 6 mo higher in non-ischemic group then with equalization at month 12 No major difference in GCs at month 12 @RheumNow #ACR25 #Abst0739 https://t.co/OeYggSQYx8

We need more biomarkers in GCA - what about fibrinogen? Miller et al retrospectively compared CRP, ESR, and fibrinogen at different points in GCA dx Fibrinogen (and ESR/CRP) only helpful prior to initiation GC with comparable performance @RheumNow #ACR25 Abst #0750 https://t.co/q5gFxDMnTy

Can tissue give us an underlying diagnosis in aortitis? Dr. Kermani breaks down the autoimmune differential based on histopathology @RheumNow #ACR25 https://t.co/twcH021dxS

2 year extension data from SELECT-GCA: Patients in remission who remained on upadacitinib 15mg daily after 1 year had 90% reduced risk of flare compared to those who switched to placebo Higher rates zoster, CK elevation in UPA group #ACR25 @RheumNow #ACRBest https://t.co/jf8Dh2wCBj

The differential diagnosis for CNS vasculitis is BROAD. Keep in mind it’s mimics @RheumNow #ACR2025 https://t.co/ASWr6zm5eQ